Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, valuing the company at $41.00 per share. The deal includes a contingent value right that will provide Apellis shareholders with two additional payments of $2.00 per share, contingent on annual global net‑sales thresholds for Syfovre®.
The acquisition brings two approved complement‑inhibitor therapies to Biogen’s portfolio: Empaveli® for rare kidney diseases and Syfovre® for geographic atrophy. In 2025, the two products generated combined net sales of $689 million, and Apellis reported a net income of $22.4 million, a turnaround from a $197.9 million loss in 2024. Biogen’s 2025 revenue was $9.9 billion, up 2% from 2024, with a non‑GAAP diluted EPS of $15.28.
Strategically, the deal expands Biogen’s growth pipeline in immunology and rare diseases and accelerates its entry into nephrology. The addition of Empaveli and Syfovre is expected to provide immediate revenue and to support the launch of felzartamab, Biogen’s anti‑CD38 antibody for kidney disease. Management highlighted that the combination of Apellis’ product expertise and Biogen’s commercial infrastructure will create a strong platform for future growth.
Market participants reacted strongly to the announcement. Analysts noted that the premium paid by Biogen reflects confidence in the long‑term value of Apellis’ complement‑based therapies, while some analysts expressed caution about the valuation relative to projected 2030 revenues. The transaction is expected to be accretive to Biogen’s non‑GAAP diluted EPS beginning in 2027 and to enhance the company’s compounded annual growth rate through the decade.
The deal is scheduled to close in the second quarter of 2026, subject to customary regulatory approvals and shareholder consent. Biogen’s board has approved the transaction, and the company will begin integrating Apellis’ operations and product lines as part of its broader strategy to diversify beyond its multiple sclerosis franchise.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.